Buy & Sell Novavax Inc (NVAX) – Novavax Inc Price Today
Aura AI Summary
Novavax (NVAX) trades at $7.99, up 3.77% in the last session, but remains in a bearish technical trend. The company reported a net loss of $187.5 million in 2024, though revenue grew to $682.16 million. Recent quarterly earnings have consistently beaten expectations, including a Q4 2025 profit of $0.11 per share versus an expected loss. Cash flow trends show persistent operational losses, but the balance sheet holds $923.12 million in cash. Analyst sentiment is predominantly bullish with a consensus price target of $17.50.
The outlook for NVAX hinges on its transition to a royalty-driven model and future profitability. Investment opportunity lies in its low valuation multiples and strong analyst buy ratings, but risks include high debt, negative equity, and dependence on successful vaccine commercialization. The stock presents a high-risk, high-reward scenario for investors betting on a turnaround.
Key Stats
- $1.30BMarket Cap
- HealthSector
- -31.19%3M Drawdown
- $812.33MEnterprise Value
- -Dividend Yield
- 50% Buy | 50% SellTrading Activity
- 58 daysTypical Hold Time
52W Low: $5.43
10 Apr 2025
52W High: $11.19
26 Feb 2026
Novavax Inc (NVAX) is currently valued at a market capitalization of $1.30B, with an enterprise value of $812.33M. Over the past 52 weeks, Novavax Inc has traded between a low of $5.43 and a high of $11.19, highlighting its annual price range. Over the past three months, Novavax Inc has recorded a drawdown of -31.19%, reflecting recent price volatility. Novavax Inc offers a dividend yield of -. On average, investors hold Novavax Inc for approximately 58 days, indicating typical investor behavior on the platform.
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Technical Indicators
|
|
|
Overall Summary
Bearish (9)Neutral (11)Bullish (7)
People also bought
US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions